Document is current

Article History

Received: 24 September 2024

Accepted: 24 November 2024

First Online: 23 January 2025

Declerations

:

: The institutional ethics committee of the Technical University of Munich approved this retrospective analysis under the reference number 115/18S. We certify that the study was performed in accordance with the ethical standards as laid down in the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards. Written informed consent was obtained from all participants.

: Not applicable.

: ME&IR report fees from Blue Earth Diagnostics Ltd. (consultant, research funding). ME reports fees from Novartis/AAA (consultant, speaker), Telix (consultant), Bayer (consultant, research funding), RayzeBio (consultant), Point Biopharma (consultant), Eckert-Ziegler (speaker), ABX GmbH (speaker) and Janssen Pharmaceuticals (consultant, speakers bureau), Parexel (image review) and Bioclinica (image review) outside the submitted work and a patent application for rhPSMA. He and other inventors are entitled to royalties on sales of 18F-flotufolastat. WW reports research support from BlueEarth Diagnostics, ITM, Novartis, and Pentixapharm. He has also acted as consultant for these companies. WW is an Associate Editor of EJNMMI. RT: Advisory boards, speaking fees; travel support, conference access; author fees; shares: Astellas, AstraZeneca, Bayer, BMS, Eisai, EUSA, Ipsen, Janssen, Merck, MSD, Novartis, Orion, Philogen, Roche, Sanofi, Thieme. No other potential conflicts of interest relevant to this article exist.